Abstract
Dengue virus (DENV), a member of the family Flaviviridae, presents a tremendous threat to global health since an estimated 2.5 billion people worldwide are at risk for epidemic transmission. DENV infections are primarily restricted to sub-tropical and tropical regions; however, there is concern that the virus will spread into new regions including the United States [1]. There are no approved antiviral drugs or vaccines to combat dengue infection, although DENV vaccines have entered Phase 3 clinical trials. Drug discovery and development efforts against DENV and other viral pathogens must overcome specificity, efficacy, safety, and resistance challenges before the shortage of licensed drugs to treat viral infections can be relieved. Current drug discovery methods are largely inefficient and thus relatively ineffective at tackling the growing threat to public health presented by emerging and remerging viral pathogens. This review discusses current and newly implemented structure-based computational efforts to discover antivirals that target the DENV NS3 protease, although it is clear that these computational tools can be applied to most disease targets.
Keywords: Dengue virus (DENV), family Flaviviridae, Dengue Protease Inhibitors, DENV vaccines, malaria, Mosquitoes
Infectious Disorders - Drug Targets
Title: New Approaches to Structure-Based Discovery of Dengue Protease Inhibitors
Volume: 9 Issue: 3
Author(s): S. M. Tomlinson, R. D. Malmstrom and S. J. Watowich
Affiliation:
Keywords: Dengue virus (DENV), family Flaviviridae, Dengue Protease Inhibitors, DENV vaccines, malaria, Mosquitoes
Abstract: Dengue virus (DENV), a member of the family Flaviviridae, presents a tremendous threat to global health since an estimated 2.5 billion people worldwide are at risk for epidemic transmission. DENV infections are primarily restricted to sub-tropical and tropical regions; however, there is concern that the virus will spread into new regions including the United States [1]. There are no approved antiviral drugs or vaccines to combat dengue infection, although DENV vaccines have entered Phase 3 clinical trials. Drug discovery and development efforts against DENV and other viral pathogens must overcome specificity, efficacy, safety, and resistance challenges before the shortage of licensed drugs to treat viral infections can be relieved. Current drug discovery methods are largely inefficient and thus relatively ineffective at tackling the growing threat to public health presented by emerging and remerging viral pathogens. This review discusses current and newly implemented structure-based computational efforts to discover antivirals that target the DENV NS3 protease, although it is clear that these computational tools can be applied to most disease targets.
Export Options
About this article
Cite this article as:
Tomlinson M. S., Malmstrom D. R. and Watowich J. S., New Approaches to Structure-Based Discovery of Dengue Protease Inhibitors, Infectious Disorders - Drug Targets 2009; 9 (3) . https://dx.doi.org/10.2174/1871526510909030327
DOI https://dx.doi.org/10.2174/1871526510909030327 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Anti-HIV Drug Distribution to the Central Nervous System
Current Pharmaceutical Design Peripheral Benzodiazepine Receptor Ligands and their Anti-Inflammatory Effects
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Molecular Imaging with Small Animal PET/CT
Current Medical Imaging Place of Nanofiltration for Assuring Viral Safety of Biologicals
Current Nanoscience Astrocyte Infection by HIV-1: Mechanisms of Restricted Virus Replication, and Role in the Pathogenesis of HIV-1-Associated Dementia
Current HIV Research Parkinsons Disease and Obsessive-Compulsive Phenomena: A Systematic Review
Current Psychiatry Reviews Amyloid-β Immunotherapy for Alzheimers Disease
CNS & Neurological Disorders - Drug Targets Therapeutic Potential of Erythropoietin in Retinal and Optic Nerve Diseases
CNS & Neurological Disorders - Drug Targets Therapeutic Targeting of Chemokines and Chemokine Receptors in Multiple Sclerosis: Opportunities and Challenges
CNS & Neurological Disorders - Drug Targets Cellular and Biochemical Actions of Melatonin which Protect Against Free Radicals: Role in Neurodegenerative Disorders
Current Neuropharmacology COVID-19: Our Current Knowledge of Epidemiology, Pathology, Therapeutic Approaches, and Diagnostic Methods
Anti-Cancer Agents in Medicinal Chemistry Porphyrin Photosensitised Processes in the Prevention and Treatment of Water- and Vector-Borne Diseases
Current Medicinal Chemistry Regulatory T Cells and Allergic Disease
Inflammation & Allergy - Drug Targets (Discontinued) Colloidal Supramolecular Aggregates for Therapeutic Application in Neuromedicine
Current Medicinal Chemistry Pharmacological Manipulation of Neural Progenitor Pathways In Situ: Possibilities for Neural Restoration in the Injured Adult Brain
Current Medicinal Chemistry - Central Nervous System Agents Pharmacological Management of Psychosis in Parkinson Disease: A Review
Current Drug Therapy Effective Biomarkers for Proof-of-Concept
Current Medical Imaging Neuroprotective Gene Therapy for Parkinson’s Disease
Current Gene Therapy GEMSP: A New Therapeutic Approach to Multiple Sclerosis
Central Nervous System Agents in Medicinal Chemistry Vaccine Development for Alzheimers Disease
Current Pharmaceutical Design